Dr Steven Leventer to head up neuroscience research for PharmaNet
pharmafile | February 17, 2010 | Appointment | Research and Development | PharmaNet, appointment, research and development
PharmaNet Development Group has named Dr Steven Leventer to the position of vice president, clinical research – neuroscience.
Leventer joins PharmaNet from Wyeth (now part of Pfizer) and was formerly vice president for central nervous system development at Quintiles.
“We are very pleased to have Steve join PharmaNet Development Group,” commented Dalvir Gill, chief operating officer of late stage development.
“Steve is a recognised expert in the fields of clinical trial design and clinical development planning. His combination of neuroscience expertise and dedication to efficiency and quality provides the right complement to our existing organisation.”
Dr Leventer has over twenty years of experience in all phases of drug development. He has spent most of his career leading clinical teams at large global pharmaceutical and contract research organisations in the development of therapeutics for Alzheimer’s disease, schizophrenia, depression and other central nervous system diseases.
Related Content
Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …
Abbott CEO to step down after 21 years
After more than two decades at the head of the company, it has emerged that …
Lonza CEO to step down in 2020
It has been announced that Marc Funk, Chief Executive Officer at Lonza, is set to …